Krishnan Suma
President, R&D
Krishnan Suma has filed 5 SEC Form 4 filings (61 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.
On the most recent filing, Krishnan Suma is listed as President, R&D at Krystal Biotech, Inc. Inside the rolling window, Krishnan Suma reported no open-market purchases and 4 open-market sales totaling $34.3M in KRYS. The largest disclosed transaction in the window is a sale of 50,000 KRYS shares on Dec 4, 2025, worth $11.0M.
Companies traded
Other insiders at KRYS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$34.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Krishnan Suma made?
Krishnan Suma has filed 5 SEC Form 4 filings (61 transaction rows) across 1 company since 2025.
Which companies does Krishnan Suma trade?
Krishnan Suma has filed SEC Form 4 disclosures for 1 company, including KRYS.
When was Krishnan Suma's most recent SEC Form 4 filing?
Krishnan Suma's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.
What is Krishnan Suma's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Krishnan Suma is listed as President, R&D.
What is Krishnan Suma's total buy and sell value in the current window?
Inside the rolling retention window, Krishnan Suma bought $0 and sold $34.3M based on SEC Form 4 filings.
What was Krishnan Suma's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 50,000 KRYS shares on 2025-12-04, worth $11.0M, per SEC Form 4 filings.